Vectura Share News (VEC)

LONDON MARKET OPEN: Tesco Leads Gains After Barclays Update

Vectura Group completes clinical trial, reveals US partner

(ShareCast News) - Vectura Group made a big step forward in the development of two of its products on Friday, VR315 and VR506, with the completion of a US clinical trial and the disclosure of its US development partner. The FTSE 250 firm described VR315 as a generic, inhaled combination therapy of f

Vectura Group Completes Clinical Trial For VR315 Asthma Treatment

Vectura Partner Ablynx Completes Enrolment For ALX-0171 Trial

BROKER RATINGS SUMMARY: Berenberg Upgrades Meggitt To Buy From Hold

Vectura Gets Milestone Payment As QVM149 Phase III Trial Begins

Vectura Loss Narrows On Better Royalty Income, Seebri Results Good

Higher royalties help lift Vectura interims

(ShareCast News) - Pharmaceutical group Vectura has posted a 57% rise in interim earnings before interest, tax, depreciation and amortisation to £4.7m driven by a 35% jump in revenues to £26.1m. Vectura, which specialises in products to treat airways-related diseases, trimmed its pre-tax losses to £

Earnings, Trading Statements Calendar - Week Ahead

LONDON MARKET CLOSE: Lower Close To Stellar October For Stocks

LONDON MARKET MIDDAY: IAG Falls After Guidance Disappoints Market

WINNERS & LOSERS SUMMARY: Investors Inhale Vectura Group Shares

LONDON MARKET OPEN: Stocks Mixed, IAG Drops Despite Guidance Upgraded

Vectura and Novartis win FDA approval for COPD combo

(ShareCast News) - Vectura and giant Swiss partner Novartis have received US drug regulator approval for their combination treatment for patients with chronic obstructive pulmonary disease (COPD), triggering a sizeable milestone payment for the UK company. The FTSE 250 drug developer and project par

Vectura Gets Two Milestone Payments From Novartis